Jazz Pharmaceuticals (JAZZ): Officer sold ~$289K
Patricia Carr, Officer at Jazz Pharmaceuticals, sold ~$289K of Jazz Pharmaceuticals shares.
- ~$289K
- Approx. value · 1,250 sh @ $231.37
- 6,675
- Holds after · shares reported
- Traded
- Nov 4, 2026
- Filed
- Nov 6, 2026
What stands out in this filing
- The sale was 15.8% of the shares this insider held before it; the filing reports 6,675 shares afterwards.
- 1,250 shares at an average of $231.37 each, as reported on the form.
- No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
The company's last weighty Form 8-K report up to this date: reported its results, 2 days earlier (Nov 2, 2026).
- InsiderCEO sold ~$486K of JAZZ shares in the open market
- InsiderOfficer sold ~$289K of JAZZ shares in the open market
- Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
- InsiderDirector sold ~$1.38M of JAZZ shares in the open market
- Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company” ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.”
- InsiderCEO sold ~$473K of JAZZ shares in the open market
- Company filing · Form 8-K · ResultsReported its results
- Company filing · Form 8-K · ResultsReported its results
- InsiderDirector sold ~$1.3M of JAZZ shares in the open market
- InsiderCEO sold ~$225K of JAZZ shares in the open market
- InsiderOfficer sold ~$289K of JAZZ shares in the open market
What came next
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Jazz Pharmaceuticals
For Jazz Pharmaceuticals, OQRO holds 25 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JAZZ page.
Other recent filings by Patricia Carr, SVP, Chief Accounting Officer
- SEC Form 4 at Jazz Pharmaceuticals (JAZZ)Nov 6, 2026
- SEC Form 4 at Jazz Pharmaceuticals (JAZZ)Mar 10, 2026
- SEC Form 4 at Jazz Pharmaceuticals (JAZZ)Mar 3, 2026
- SEC Form 4 at Jazz Pharmaceuticals (JAZZ)Mar 3, 2026
- SEC Form 4 at Jazz Pharmaceuticals (JAZZ)Dec 10, 2025
The full history of Patricia Carr, SVP, Chief Accounting Officer is on the profile page.
How this filing works
Explore the data
Common questions
Which Jazz Pharmaceuticals (JAZZ) insider traded, and how much?
Patricia Carr, Officer at Jazz Pharmaceuticals, sold ~$289K of Jazz Pharmaceuticals shares. 1,250 shares at $231.37.
When did it happen, and when was it made public?
Traded: Nov 4, 2026. Filed: Nov 6, 2026. That is 2 days between the two dates.
What stands out in this filing?
The sale was 15.8% of the shares this insider held before it; the filing reports 6,675 shares afterwards. 1,250 shares at an average of $231.37 each, as reported on the form. No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Jazz Pharmaceuticals recently?
For Jazz Pharmaceuticals, OQRO holds 25 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the JAZZ page.
Does this mean JAZZ stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Jazz Pharmaceuticals
- SEC Form 4Nov 10, 2026
- SEC Form 4Nov 10, 2026
- SEC Form 4Nov 10, 2026
- SEC Form 4Nov 10, 2026
- SEC Form 144Nov 6, 2026
- SEC Form 4Nov 6, 2026
Everything OQRO holds on this company is on its JAZZ page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
